TABLE 1.
Baseline characteristics of included patients
| Characteristics | Overall population (N = 27) |
|---|---|
| Age (year) | 56.7 |
| Gender, n (%) | |
| Male | 21 (77.8%) |
| Female | 6 (22.2%) |
| Histology, n (%) | |
| Adenocarcinoma | 20 (74.1%) |
| Squamous | 5 (18.5%) |
| Others | 2 (7.4%) |
| Stage, n (%) | |
| III | 2 (7.4%) |
| IV | 25 (92.6%) |
| ECOG PS, n (%) | |
| 0 | 8 (29.6%) |
| 1 | 19 (70.4%) |
| Metastasis sites, n (%) | |
| Pleural | 8 (29.6%) |
| Brain | 3 (11.1%) |
| Other sites | 14 (51.9%) |
| None | 2 (7.4%) |
| PD‐L1 tumor proportion score, n (%) | |
| <1% | 21 (77.8%) |
| ≥1% | 5 (18.5%) |
| 1–49% | 3 (11.1%) |
| ≥50% | 2 (7.4%) |
| Could not be evaluated | 1 (3.7%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD‐L1, programmed cell death ligand 1.